The effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with malignant peritoneal mesothelioma: A tertiary center experience Malign peritoneal mezotelyoma hastalarýnda sitoredüktif cerrahi ve hipertermik ýntraperitoneal kemoterapi (HIPEC) etkinliği: Tersiyer bir merkez deneyimi
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, cilt.28, sa.1, ss.11-18, 2018 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 28 Sayı: 1
- Basım Tarihi: 2018
- Doi Numarası: 10.4999/uhod.182308
- Dergi Adı: UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.11-18
- Anahtar Kelimeler: Malignant mesothelioma, Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy, Survival, Mortality
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
In this study, we aimed to investigate the effect of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures on overall survival (OS), morbidity, and mortality rates in patients with malignant peritoneal mesothelioma (MPM), an extremely rare tumor. Between January 2012 and March 2017, 21 patients who were diagnosed with a MPM and underwent CRS plus HIPEC were retrospectively analyzed. The median age was 60 (range, 18 to 80) years. Eighteen patients (76.2%) had a history of exposure to asbestos. The median follow-up was 17 months (range, 1 to 36 months). The median OS was 26 months. The rates of OS at 12, 24, and 36 months were 80%, 80%, and 40.5%, respectively. The perioperative mortality and morbidity rates were 4.8% and 33.3%, respectively. The 3-year survival rate was 93.8 % for patients treated with a CC 0 or 1 resection, whereas the median OS was 6 months for those treated with a CC 2 or 3 resection (p= 0.007). Age, gender, smoking status, asbestos exposure, pathological type, peritoneal cancer index (PCI), lymph node involvement, ascites, and cancer antigen (CA)-125 were not found to significantly influence the OS in univariate analysis (p> 0.05). A successful CRS plus HIPEC in selected patients with MPM seems to have beneficial effects on OS. In addition, our morbidity and mortality rates are consistent with the current literature.